letrozole

Femara

Pharmacologic class: Aromatase inhibitor

Therapeutic class: Antineoplastic

Pregnancy risk category D

Action

Inhibits aromatase, an enzyme that promotes conversion of estrogen precursors to estrogen. This inhibition reduces circulating estrogen levels and stops progression of breast cancer.

Availability

Tablets: 2.5 mg

Indications and dosages

➣ Metastatic or advanced breast cancer in postmenopausal women; early breast cancer in postmenopausal women who have received 5 years of antiestrogen therapy

Adults: 2.5 mg P.O. daily

Contraindications

• Hypersensitivity to drug or its components

Precautions

Use cautiously in:

• severe hepatic impairment

• pregnant or breastfeeding patients

• children (safety not established).

Administration

• Give with or without meals.

Adverse reactions

CNS: anxiety, depression, dizziness, drowsiness, fatigue, headache, vertigo, asthenia

CV: chest pain, hypertension

EENT: blurred vision

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia

Metabolic: hypercalcemia

Musculoskeletal: musculoskeletal or joint pain, fractures

Respiratory: cough, dyspnea, pleural effusion

Skin: alopecia, pruritus, rash, diaphoresis

Other: hot flashes, edema, weight gain, angioedema, anaphylactic reactions

Interactions

Drug-diagnostic tests. Cholesterol, gamma-glutamyltransferase: increased levels

Patient monitoring

• Check vital signs and assess cardiovascular and respiratory status.

• Monitor renal and hepatic function, electrolyte levels, and lipid panels.

• Assess for adverse CNS effects, including depression. Institute safety measures as needed to prevent injury.

Patient teaching

• Tell patient she can take with or without food.

• Instruct patient to weigh herself regularly and report significant changes.

• Advise patient and family to watch for signs and symptoms of depression.

• Tell patient to minimize GI upset by eating small, frequent servings of healthy food and drinking plenty of fluids.

• Caution patient to avoid driving and other hazardous activities until she knows how drug affects concentration and alertness.

• Inform patient that treatment is long term. Urge her to keep follow-up appointments with prescriber.

• Tell patient to inform prescriber if she is pregnant or breastfeeding.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.

letrozole

(lĕt′rə-zōl′)n. A nonsteroidal drug, C₁₇H₁₁N₅, that inhibits the enzyme aromatase and is used to treat breast cancer in postmenopausal women.

letrozole

An AROMATASE INHIBITOR drug used to treat breast cancer in menopausal women that has resisted anti-oestrogen drugs. Adjuvant treatment with letrozole in post-menopausal women with breast cancer appears to be more effective than tamoxifen in reducing the risk of recurrence. A brand name is Femara.

单词	letrozole
释义	letrozole let·ro·zole L5137500 (lĕt′rə-zōl′)n. A nonsteroidal drug, C₁₇H₁₁N₅, that inhibits the enzyme aromatase and is used to treat breast cancer in postmenopausal women. [le-, of unknown origin + alteration of triazole.] letrozole (ˈlɛtrəˌzəʊl) n (Pharmacology) an anti-oestrogen drug used in the treatment of breast cancer in post-menopausal women. Also called (trademark): Femara letrozole letrozole Femara *Pharmacologic class:* Aromatase inhibitor *Therapeutic class:* Antineoplastic *Pregnancy risk category D* Action Inhibits aromatase, an enzyme that promotes conversion of estrogen precursors to estrogen. This inhibition reduces circulating estrogen levels and stops progression of breast cancer. Availability Tablets: 2.5 mg Indications and dosages ➣ Metastatic or advanced breast cancer in postmenopausal women; early breast cancer in postmenopausal women who have received 5 years of antiestrogen therapy Adults: 2.5 mg P.O. daily Contraindications • Hypersensitivity to drug or its components Precautions Use cautiously in: • severe hepatic impairment • pregnant or breastfeeding patients • children (safety not established). Administration • Give with or without meals. Adverse reactions CNS: anxiety, depression, dizziness, drowsiness, fatigue, headache, vertigo, asthenia CV: chest pain, hypertension EENT: blurred vision GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia Metabolic: hypercalcemia Musculoskeletal: musculoskeletal or joint pain, fractures Respiratory: cough, dyspnea, pleural effusion Skin: alopecia, pruritus, rash, diaphoresis Other: hot flashes, edema, weight gain, angioedema, anaphylactic reactions Interactions Drug-diagnostic tests. Cholesterol, gamma-glutamyltransferase: increased levels Patient monitoring • Check vital signs and assess cardiovascular and respiratory status. • Monitor renal and hepatic function, electrolyte levels, and lipid panels. • Assess for adverse CNS effects, including depression. Institute safety measures as needed to prevent injury. Patient teaching • Tell patient she can take with or without food. • Instruct patient to weigh herself regularly and report significant changes. • Advise patient and family to watch for signs and symptoms of depression. • Tell patient to minimize GI upset by eating small, frequent servings of healthy food and drinking plenty of fluids. • Caution patient to avoid driving and other hazardous activities until she knows how drug affects concentration and alertness. • Inform patient that treatment is long term. Urge her to keep follow-up appointments with prescriber. • Tell patient to inform prescriber if she is pregnant or breastfeeding. • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above. letrozole (lĕt′rə-zōl′)n. A nonsteroidal drug, C₁₇H₁₁N₅, that inhibits the enzyme aromatase and is used to treat breast cancer in postmenopausal women. letrozole An AROMATASE INHIBITOR drug used to treat breast cancer in menopausal women that has resisted anti-oestrogen drugs. Adjuvant treatment with letrozole in post-menopausal women with breast cancer appears to be more effective than tamoxifen in reducing the risk of recurrence. A brand name is Femara.
随便看	sudden deafness sudden death sudden-death sudden death factors sudden death failure period sudden death in custody sudden death overtime sudden deaths sudden death syndrome sudden enhancement of atmospheres sudden enhancement of signal sudden-expansion flow chamber sudden hearing loss sudden infant death sudden infant death research foundation sudden infant death syndrome sudden infant death syndrome, risk for sudden infant death syndromes sudden infant death with dysgenesis of the testes syndrome sudden instant recall effect sudden ionospheric disturbance sudden jargon-specific brain freeze sudden jihad syndrome sudden loss of wealth syndrome suddenly

letrozole

let·ro·zole

letrozole

letrozole

letrozole

Action

Availability

Indications and dosages

Contraindications

Precautions

Administration

Adverse reactions

Interactions

Patient monitoring

Patient teaching

letrozole

letrozole